Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AssigneeSeattle Genetics, Inc.
InventorsChe-Leung Law, Alan Wahl, Nathalie Scholler, Linda Pestano
Life of this patent
Estimating the term…
Abstract
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
Claims104
A method for the treatment of a CD70-expressing cancer in a subject, the method comprising:
- administering to the subject, in an amount effective for the treatment, an antibody-drug conjugate comprising an antibody that binds to CD70 and wherein the drug is a cytotoxic or cytostatic agent.
A method for the treatment of an immunological disorder in a subject, the method comprising:
- administering to the subject, in an amount effective for the treatment, an antibody-drug conjugate comprising an antibody that binds CD70 and wherein the antibody is conjugated to a cytotoxic agent or an immunosuppressive agent.
An antibody-drug conjugate comprising:
- an antibody that binds to CD70 and is conjugated to a cytotoxic agent or an immunosuppressive agent, wherein the antibody-drug conjugate exerts (a) a cytotoxic or cytostatic effect on a CD70-expressing cancer cell line or (b) a cytotoxic, cytostatic, or immunosuppressive effect on a CD70-expressing immune cell.
Dependencies are inferred from the claim text.